Logo

GSK and Medicago to Initiate P-I Trial of Plant-Based COVID-19 Vaccine in July 2020

Share this

GSK and Medicago to Initiate P-I Trial of Plant-Based COVID-19 Vaccine in July 2020

Shots:

  • The two companies collaborated to develop a COVID-19 vaccine combining Medicago’s recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK’s pandemic adjuvant system. The partners are planning to initiate P-I study in mid-July followed by pre-clinical results that showed combining the two platforms demonstrated a high level of neutralizing Abs following a single dose
  • The study will evaluate the safety and immunogenicity of three different dose levels of antigen combined with GSK’s adjuvant and compared it with adjuvant of another company- administered on a one- and two-dose vaccination schedule- given 21 days apart
  • Medicago will leverage its plant-based production platform to manufacture the COVID-19 vaccine antigen by using the leaves of a plant as bioreactors to produce the S-spike protein which self-assembles into VLPs for use in the CoVLP vaccine candidate. The companies aim to complete the development and make it available in H1’21 and expect to manufacture ~100M doses by the end of 2021

Ref: GSK | Image: GSK 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions